Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center FDA Record
- Latest inspection VAI · Dec 2, 2022
- 3 Class I recalls
- Last warning letter 2022
Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center has 89 FDA recalls (3 Class I), 2 inspections, 3 510(k) clearances and 0 compliance actions on record. FDA has issued 1 warning letter to Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center, the most recent on Oct 21, 2022. FDA has published 7 Form 483s for Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center.
- Latest recall
- D-0257-2025 · Class II · Feb 10, 2025
- Latest inspection
- Dec 2, 2022 · VAI
- Latest 510(k)
- Feb 9, 2023
Summary
| Records | Count | Last refreshed | Source as of | Status |
|---|---|---|---|---|
| Recalls | 89 (3 Class I) | Nov 11, 2026 (checked Nov 15, 2026, unchanged) | File dated Nov 10, 2026 | Current |
| 510(k) clearances | 3 | Nov 15, 2026 | File dated Nov 9, 2026 | Current |
| Inspections | 2 | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Compliance actions | 0 | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
FDA record by year
Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center: FDA inspections per year
| Year | Inspections | OAI | Warning letters | Recall records | Class I |
|---|---|---|---|---|---|
| 2026 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 1 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 9 | 0 |
| 2022 | 1 | 0 | 0 | 63 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2019 | 0 | 0 | 0 | 6 | 0 |
| 2018 | 0 | 0 | 0 | 0 | 0 |
| 2017 | 0 | 0 | 0 | 0 | 0 |
Reviewing Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center FDA Warning Letters
| Issued | Subject | Issuing office | Close-out letter |
|---|---|---|---|
| Oct 21, 2022 · Letter on fda.gov | Compounding Pharmacy/Adulterated Drug Products | Office of Pharmaceutical Quality Operations, Division II |
Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center Form 483s
Recent recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0257-2025 | Class II | Sodium Chloride Injection 9%, USP, 500 mL, Single-Dose IV Bottle, Rx Only, nephron, 503B outsourcing… | Feb 10, 2025 |
| D-0359-2023 | Class II | Phenylephrine HCl Injection, USP, 1 mg/10 mL (100 mcg/mL), 10 mL Single-Dose Vial, packaged in 30 x… | Feb 22, 2023 |
| D-0362-2023 | Class II | Phenylephrine HCl in 0.9% Sodium Chloride Injection, USP, 50 mg/250 mL (200 mcg/mL), 250 mL… | Feb 22, 2023 |
| D-0357-2023 | Class II | Norepinephrine Bitartrate in 0.9% Sodium Chloride Injection, USP, 4 mg/250 mL (16 mcg/mL*), 250 mL… | Feb 22, 2023 |
| D-0361-2023 | Class II | Phenylephrine HCl Injection, USP, 0.8 mg/10 mL (80 mcg/mL), 10 mL Single-Dose Vial, packaged in 30 x… | Feb 22, 2023 |
| D-0356-2023 | Class II | Norepinephrine Bitartrate in 0.9% Sodium Chloride Injection, USP, 8 mg/250 mL (32 mcg/mL*), 250 mL… | Feb 22, 2023 |
| D-0355-2023 | Class II | Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (1 mg/mL), 125 mL Single-Dose… | Feb 22, 2023 |
| D-0360-2023 | Class II | Phenylephrine HCl Injection, USP, 0.4 mg/10 mL (40 mcg/mL), 10 mL Single-Dose Vial, packaged in 30 x… | Feb 22, 2023 |
| D-0358-2023 | Class II | Norepinephrine Bitartrate in 0.9% Sodium Chloride Injection, USP, 16 mg/250 mL (64 mcg/mL*), 250 mL… | Feb 22, 2023 |
| D-0099-2023 | Class II | Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL), 5 x 5 mL Pre-Filled Syringe, 6 x 5 syringe… | Jan 6, 2023 |
| D-0065-2023 | Class II | PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B… | Nov 10, 2022 |
| D-0064-2023 | Class II | PF-Labetalol HCl Injection, USP 20 mg/4 mL (5 mg/mL) vial, Rx Only, Nephron 503B Outsourcing… | Nov 10, 2022 |
| D-1344-2022 | Class II | PF-Neostigmine Methylsulfate Injection, USP, 3 mg/3 mL (1 mg/mL), One 3 mL Unit-Dose Vial, packaged… | Aug 10, 2022 |
| D-1347-2022 | Class II | PF-Labetalol HCl Injection, USP, 20 mg/4 mL (5 mg/mL), One 4 mL Unit-Dose Vial, packaged in 30 x 4… | Aug 10, 2022 |
| D-1345-2022 | Class II | Trisodium Citrate 0.5% Solution, (0.5%/4L), contains Per Liter: Sodium 140 mmol/L, Chloride 86… | Aug 10, 2022 |
| D-1346-2022 | Class II | PF-0.125% Bupivacaine HCl Injection, USP, 625 mg/500 mL (1.25 mg/mL), 500 mL bag, packaged in 10 x 1… | Aug 10, 2022 |
| D-1256-2022 | Class II | HYDROmorphone HCl Injection, USP, 6 mg/30 mL (0.2 mg/mL) syringes, 5 x 30 mL Pre-Filled Syringes per… | Jun 30, 2022 |
| D-1258-2022 | Class II | HYDROmorphone HCl Injection, USP, 50 mg/50 mL (1 mg/mL) syringes, packaged in 5 x 50 mL Pre-Filled… | Jun 30, 2022 |
| D-1277-2022 | Class II | Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) syringe, packaged in 5 x 5 mL Pre-Filled… | Jun 30, 2022 |
| D-1268-2022 | Class II | Morphine Sulfate Injection, USP, 1 mg/mL syringe, packaged in 5 x 1 mL Pre-Filled Syringes per… | Jun 30, 2022 |
Recent FDA inspections
| Date | Site | Product | Classification | FEI |
|---|---|---|---|---|
| Dec 2, 2022 | Murray, KY | Drugs | Voluntary Action Indicated (VAI) | 3010247115 |
| Nov 4, 2008 | Mountain Home, ID | Drugs | No Action Indicated (NAI) | 3004462991 |
- NAI
- No objectionable conditions or practices were found during the inspection.
- VAI
- Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
- OAI
- Regulatory and/or administrative actions are recommended.
FDA-inspected facilities
| Facility | Location | Inspections | Latest |
|---|---|---|---|
| FEI 3010247115 | Murray, KY | 1 | Dec 2, 2022 |
| FEI 3004462991 | Mountain Home, ID | 1 | Nov 4, 2008 |
Recent 510(k) clearances
| K-Number | Device | Date |
|---|---|---|
| K223559 | Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs) | Feb 9, 2023 |
| K113033 | SODIUM CHLORDE INHALATION SOLUTION, 0.9% USP-3ML | Jun 19, 2012 |
| K120051 | SODIUM CHLORIDE INHALATION SOLUTION, 3%, 7%, AND 10%, USP-4ML | Apr 20, 2012 |
Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center and the FDA: common questions
Has Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center received an FDA warning letter?
Yes. FDA has issued 1 warning letter to Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center. The most recent is dated Oct 21, 2022, with the subject "Compounding Pharmacy/Adulterated Drug Products".
Has Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center received an FDA Form 483?
FDA has published 7 Form 483s for Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center in its reading room, the most recent dated Sep 25, 2024. FDA publishes some Form 483s, not all of them.
When did the FDA last inspect Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center?
The most recent FDA inspection on file ended Dec 2, 2022 at Murray, KY and was classified VAI. FDA has 2 inspections of Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center on file.
Has Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center had an FDA recall?
Yes. Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center has 89 FDA recalls on record, 3 of them Class I, the most serious class. The most recent started Feb 10, 2025.
Need more than this page shows? Ask about Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.